Please sign in so that we can notify you about a reply
Indications/Uses
Acute maxillary sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis etc.
Acute bacterial exacerbation of chronic bronchitis (ABECB) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis etc.
Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, E. coli, Klebsiella pneumoniae, Haemophilus influenzae or Streptococcus pneumoniae etc.
Community-acquired pneumonia (CAP) due to Klebsiella pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae or Moraxella catarrhalis etc.
Complicated and uncomplicated urinary tract infections due to E. coli, Klebsiella pneumoniae, Staphylococcus aureus or Staphylococcus aprophyticus, Proteus mirabilis, Enterococcus faecalis or Enterobacter cloacae etc.
Acute pyelonephritis due to E. coli etc.
Complicated and uncomplicated skin and skin structure infections including abscesses, cellulitis, furuncles, wound infection, impetigo and pyoderma due to Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis or Enterococcus faecalis etc.
Chronic bacterial prostatitis due to Enterococcus faecalis, E. coli, or Staphylococcus epidermidis etc.
Acute bacterial exacerbation of chronic bronchitis (ABECB) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis etc.
Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, E. coli, Klebsiella pneumoniae, Haemophilus influenzae or Streptococcus pneumoniae etc.
Community-acquired pneumonia (CAP) due to Klebsiella pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae or Moraxella catarrhalis etc.
Complicated and uncomplicated urinary tract infections due to E. coli, Klebsiella pneumoniae, Staphylococcus aureus or Staphylococcus aprophyticus, Proteus mirabilis, Enterococcus faecalis or Enterobacter cloacae etc.
Acute pyelonephritis due to E. coli etc.
Complicated and uncomplicated skin and skin structure infections including abscesses, cellulitis, furuncles, wound infection, impetigo and pyoderma due to Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis or Enterococcus faecalis etc.
Chronic bacterial prostatitis due to Enterococcus faecalis, E. coli, or Staphylococcus epidermidis etc.
Dosage/Direction for Use
Levofloxacin can be administered without regards to food. The usual dose of Levofloxacin is 500 mg once or twice daily.
Dosage guideline: (See Table.)
Dosage guideline: (See Table.)
OR AS DIRECTED BY THE PHYSICIAN.
Administration
May be taken with or without food: Ensure adequate fluid intake.
Contraindications
Levofloxacin is contraindicated in patients with a history of hypersensitivity to Levofloxacin, quinolones or any other components of this product.
Special Precautions
Levofloxacin cause degenerative changes in weight-bearing joints of young animals, it has been suggested that these compounds should not be used in children, adolescents, pregnant women, or breast-feeding mothers. Tendon damage may occur rarely with fluoroquinolones (see Effects on the Musculoskeletal System), and treatment should be discontinued if patients experience tendon pain, inflammation, or rupture.
Care is necessary in patients with impaired hepatic or renal function, glucose-6-phosphate dehydrogenase deficiency, or myasthenia gravis. An adequate fluid intake should be maintained during treatment with ciprofloxacin and excessive alkalinity of the urine avoided because of the risk of crystalluria. Exposure to strong sunlight or sunlamps should also be avoided. The ability to drive or operate machinery may be impaired.
Care is necessary in patients with impaired hepatic or renal function, glucose-6-phosphate dehydrogenase deficiency, or myasthenia gravis. An adequate fluid intake should be maintained during treatment with ciprofloxacin and excessive alkalinity of the urine avoided because of the risk of crystalluria. Exposure to strong sunlight or sunlamps should also be avoided. The ability to drive or operate machinery may be impaired.
Adverse Reactions
Nausea, vomiting, diarrhea, abdominal pain & dyspepsia. Headache, dizziness, restlessness, nervousness & insomnia. Occassionally, pruritus, erythematous rash.
Drug Interactions
Interact with Theophylline, Warfarin, Cyclosporin, Digoxin, Probenecid, Cimetidine, Sucralfate, Antacid, NSAIDs.
Caution For Usage
Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.
Storage
Store at temperatures not exceeding 30°C. Protect from light.
Action
Pharmacology: Pharmacokinetics: Levofloxacin is rapidly and almost completely absorbed following oral administration with peak plasma concentrations achieved within an hour of a dose. It is distributed into body tissues including the bronchial mucosa and lungs, but penetration into CSF is relatively poor. Levofloxacin is approximately 30 to 40% bound to plasma proteins. It is only metabolised to a small degree to inactive metabolites. The elimination half-life of levofloxacin is 6 to 8 hours, although this may be prolonged in patients with renal impairment. Levofloxacin is excreted largely unchanged, primarily in the urine. It is not removed by haemodialysis or peritoneal dialysis.
MedsGo Class
Quinolones
Features
Brand
Levomax
Full Details
Dosage Strength
500 mg
Drug Ingredients
- Levofloxacin
Drug Packaging
Film-Coated Tablet 20's
Generic Name
Levofloxacin Hemihydrate
Dosage Form
Film-Coated Tablet
Registration Number
DRP-1726
Drug Classification
Prescription Drug (RX)
Product Questions
Questions
